KR101682728B1 - 신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제 - Google Patents

신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제 Download PDF

Info

Publication number
KR101682728B1
KR101682728B1 KR1020117002132A KR20117002132A KR101682728B1 KR 101682728 B1 KR101682728 B1 KR 101682728B1 KR 1020117002132 A KR1020117002132 A KR 1020117002132A KR 20117002132 A KR20117002132 A KR 20117002132A KR 101682728 B1 KR101682728 B1 KR 101682728B1
Authority
KR
South Korea
Prior art keywords
amount
leu
biological sample
pro
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117002132A
Other languages
English (en)
Korean (ko)
Other versions
KR20110049781A (ko
Inventor
한스-울리히 데무트
슈테판 쉴링
마틴 클라인슈미트
얀스-울리히 라펠트
아스트리트 켈렌
모니크 보낙
Original Assignee
프로비오드룩 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41256108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101682728(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프로비오드룩 아게 filed Critical 프로비오드룩 아게
Publication of KR20110049781A publication Critical patent/KR20110049781A/ko
Application granted granted Critical
Publication of KR101682728B1 publication Critical patent/KR101682728B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117002132A 2008-07-31 2009-07-31 신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제 Active KR101682728B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8515408P 2008-07-31 2008-07-31
US61/085,154 2008-07-31
PCT/EP2009/059951 WO2010012828A2 (en) 2008-07-31 2009-07-31 Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
KR20110049781A KR20110049781A (ko) 2011-05-12
KR101682728B1 true KR101682728B1 (ko) 2016-12-05

Family

ID=41256108

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117002132A Active KR101682728B1 (ko) 2008-07-31 2009-07-31 신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제

Country Status (15)

Country Link
US (3) US20100028918A1 (OSRAM)
EP (1) EP2329274B1 (OSRAM)
JP (1) JP5677297B2 (OSRAM)
KR (1) KR101682728B1 (OSRAM)
CN (2) CN103983787A (OSRAM)
AU (1) AU2009275869B2 (OSRAM)
BR (1) BRPI0916601B1 (OSRAM)
CA (1) CA2731933A1 (OSRAM)
EA (1) EA025107B1 (OSRAM)
IL (1) IL210266A (OSRAM)
MX (1) MX2011001093A (OSRAM)
NZ (1) NZ590658A (OSRAM)
SG (1) SG193148A1 (OSRAM)
WO (1) WO2010012828A2 (OSRAM)
ZA (1) ZA201100177B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240173871A (ko) * 2023-06-07 2024-12-16 계명대학교 산학협력단 Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519891A (ja) * 2010-02-18 2013-05-30 プロビオドルグ エージー ピログルタミン酸修飾ｍｃｐ−１を決定することにより炎症性疾患を診断する方法及びグルタミニルシクラーゼの阻害剤のスクリーニング方法
JP2014515364A (ja) 2011-05-27 2014-06-30 プロビオドルグ エージー 放射能標識グルタミニルシクラーゼ阻害剤
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
CN104946680A (zh) * 2015-06-11 2015-09-30 深圳大学 用于表达qc的重组载体及其制备方法、引物、基因工程菌
KR102362919B1 (ko) * 2016-07-08 2022-02-16 아지노모토 가부시키가이샤 경도 인지 장해 또는 알츠하이머형 인지증의 평가 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175626A1 (en) 2002-07-24 2005-08-11 Andre Delacourte Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
US20070191366A1 (en) 2003-05-05 2007-08-16 Torsten Hoffmann Use of effectors of glutaminyl and glutamate cyclases
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
WO2008087197A1 (en) 2007-01-19 2008-07-24 Probiodrug Ag In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
JP3590468B2 (ja) * 1996-01-22 2004-11-17 財団法人 東京都医学研究機構 アルツハイマー病診断薬
MXPA05011861A (es) * 2003-05-05 2006-02-17 Probiodrug Ag Uso de efectores de ciclasas de glutamato y glutaminil.
CA2542419C (en) * 2003-10-15 2013-06-04 Probiodrug Ag Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
WO2006120104A1 (en) * 2005-04-11 2006-11-16 Probiodrug Ag Inhibitors of prolyl endopeptidase
ATE523788T1 (de) * 2006-06-08 2011-09-15 Fu Berlin ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175626A1 (en) 2002-07-24 2005-08-11 Andre Delacourte Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
US20070191366A1 (en) 2003-05-05 2007-08-16 Torsten Hoffmann Use of effectors of glutaminyl and glutamate cyclases
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
WO2008087197A1 (en) 2007-01-19 2008-07-24 Probiodrug Ag In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240173871A (ko) * 2023-06-07 2024-12-16 계명대학교 산학협력단 Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물
KR102858457B1 (ko) 2023-06-07 2025-09-11 계명대학교 산학협력단 Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물

Also Published As

Publication number Publication date
US20150247180A1 (en) 2015-09-03
BRPI0916601B1 (pt) 2021-05-25
SG193148A1 (en) 2013-09-30
JP2011529571A (ja) 2011-12-08
NZ590658A (en) 2012-07-27
HK1155813A1 (en) 2012-05-25
ZA201100177B (en) 2012-02-29
IL210266A0 (en) 2011-03-31
US20170097365A1 (en) 2017-04-06
CN103983787A (zh) 2014-08-13
IL210266A (en) 2016-04-21
EP2329274A2 (en) 2011-06-08
KR20110049781A (ko) 2011-05-12
JP5677297B2 (ja) 2015-02-25
CA2731933A1 (en) 2010-02-04
US20100028918A1 (en) 2010-02-04
EA025107B1 (ru) 2016-11-30
CN102112880A (zh) 2011-06-29
WO2010012828A3 (en) 2010-05-06
MX2011001093A (es) 2011-03-15
WO2010012828A2 (en) 2010-02-04
EA201100253A1 (ru) 2011-10-31
EP2329274B1 (en) 2015-12-02
CN102112880B (zh) 2014-06-25
BRPI0916601A2 (pt) 2015-11-10
AU2009275869A1 (en) 2010-02-04
AU2009275869B2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
Pera et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
US9733260B2 (en) Biochemical markers for neurodegenerative conditions
US20110166035A1 (en) Novel diagnostic method
AU2007357025B2 (en) High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
US20170097365A1 (en) Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases
WO2011033046A1 (en) Novel assay for the detection of amyloid beta peptides
CN102947705A (zh) 通过确定焦谷氨酸修饰的mcp-1诊断炎性疾病的方法和谷氨酰胺酰基环化酶抑制剂的筛选方法
WO2008031190A1 (en) Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases
EP2653872B1 (en) Biomarker for amyloid-beta -related neurological disorders
US20170030929A1 (en) Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins
Gonzales et al. Development of a specific ELISA to measure BACE1 levels in human tissues
HK1197762A (en) Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
HK1155813B (en) Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
Magini et al. Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer's disease patients share a unique protein levels profile
Class et al. Patent application title: NOVEL DIAGNOSTIC METHOD Inventors: Martin Kleinschmidt (Halle/saale, DE) Martin Kleinschmidt (Halle/saale, DE) Claudia Goettlich (Halle/saale, DE) Hans-Ulrich Demuth (Halle/saale, DE) Jens-Ulrich Rahfeld (Ot Roeblingen Am See, DE) Assignees: PROBIODRUG AG

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20191126

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20201118

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20211118

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20221121

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10